<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05114759</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-A2009-I-101</org_study_id>
    <nct_id>NCT05114759</nct_id>
  </id_info>
  <brief_title>A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Open-Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A2009 for Injection in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, multicenter Phase I clinical trial to evaluate the safety,&#xD;
      tolerability, pharmacokinetics and efficacy of SHR-A2009 for injection in patients with&#xD;
      advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm study of SHR-A2009</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) or maximum administered dose (MAD).</measure>
    <time_frame>From Day 1 to Day 21</time_frame>
    <description>Incidence and category of dose limiting toxicities (DLTs) during the first 21-day cycle of SHR-A2009 treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 dose (RP2D)</measure>
    <time_frame>From Day 1 to 90 days after last dose</time_frame>
    <description>RP2D will be determined on the basis of evaluation on MTD/MAD, PK, efficacy data in dose escalation and dose expansion stages.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) ([CTCAE] v5.0)</measure>
    <time_frame>From Day 1 to 90 days after last dose</time_frame>
    <description>Assess safety and tolerability of SHR-A2009 by way of adverse events (CTCAE v5.0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax of SHR-A2009</measure>
    <time_frame>approximately 6 months</time_frame>
    <description>Time to maximum concentration of SHR-A2009</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of SHR-A2009</measure>
    <time_frame>approximately 6 months</time_frame>
    <description>Maximum concentration of SHR-A2009</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t of SHR-A2009</measure>
    <time_frame>approximately 6 months</time_frame>
    <description>area under the concentration-time curve from time 0 to the last measurable concentration time point of SHR-A2009</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ of SHR-A2009</measure>
    <time_frame>approximately 6 months</time_frame>
    <description>area under the concentration-time curve from time 0 to infinity of SHR-A2009</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of SHR-A2009</measure>
    <time_frame>approximately 9 months</time_frame>
    <description>Anti-SHR-A2009 antibody (ADA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>approximately within 36 months</time_frame>
    <description>Evaluated using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>approximately within 36 months</time_frame>
    <description>Evaluated using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>approximately within 36 months</time_frame>
    <description>Evaluated using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>approximately within 36 months</time_frame>
    <description>Evaluated using RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>SHR-A2009 for Injection will be administrated per dose level in which the patients are assigned.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-A2009</intervention_name>
    <description>In dose Escalation:&#xD;
SHR-A2009 will be administered intravenously. Six dose levels are preset.&#xD;
In dose Expansion:&#xD;
2 to 3 dose cohorts will be selected for dose expansion stage.&#xD;
In indication Expansion:&#xD;
Indications will be selected to evaluate preliminary efficacy.</description>
    <arm_group_label>SHR-A2009 for Injection will be administrated per dose level in which the patients are assigned.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically or cytologically confirmed unresectable locally advanced&#xD;
             or metastatic solid tumors which is relapsed or refractory to standard treatment, or&#xD;
             lack of standard treatment, or standard treatment is not applicable currently;&#xD;
&#xD;
          2. Have at least one measurable tumor lesion per RECIST v1.1 (patients with only&#xD;
             non-target lesions are allowed to be enrolled in dose escalation stage);&#xD;
&#xD;
          3. ECOG performance status of 0-1;&#xD;
&#xD;
          4. Life expectancy ≥ 12 weeks;&#xD;
&#xD;
          5. Adequate bone marrow and organ function .&#xD;
&#xD;
          6. Subjects must voluntarily agree to participate in the trial and sign a written&#xD;
             informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with symptomatic central nervous system metastases or meningeal metastases;&#xD;
&#xD;
          2. Ongoing or previous anti-tumor therapies within 4 weeks prior to the first dose of&#xD;
             study drug;&#xD;
&#xD;
          3. Prior treatment with antibody-drug conjugate (ADC) consisting of topoisomerase I&#xD;
             inhibitors;&#xD;
&#xD;
          4. History of serious cardiovascular and cerebrovascular diseases;&#xD;
&#xD;
          5. Severe infection within 4 weeks prior to the first dose;&#xD;
&#xD;
          6. Adverse reactions of previous anti-tumor treatment have not recovered to Grade ≤ 1 per&#xD;
             NCI-CTCAE v5.0.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wei Shi, MD, PhD</last_name>
    <phone>+86 021-61053363</phone>
    <email>wei.shi@hengrui.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

